share_log

【BT财报瞬析】科华生物2023三季报:资产负债率下降,营业收入和净利润受压

[BT Financial Report Instantaneous Analysis] Kehua Biotech's 2023 Quarterly Report: Balance Ratio Declines, Operating Income and Net Profit Are Under Pressure

businesstimes cn ·  11/03/2023 16:20

Announcement time of this financial report: 2023-10-27 19:37:28

Kehua Biotech (stock code: 002022) is a medical device company focusing on the manufacture of in vitro diagnostic products. It is mainly engaged in R&D, production and sales of in vitro diagnostic reagents and medical testing instruments. In vitro diagnosis plays an important role in clinical diagnosis. It can provide important reference indicators for doctors' treatment plans and medication, and at the same time save medical expenses.

Judging from Kehua Biotech's 2023 three-quarter report, the company's total assets fell from 8.813 billion yuan at the end of the previous year to 7.038 billion yuan at the end of this reporting period, and total liabilities fell from 2,961 billion yuan at the end of the previous year to 1,813 billion yuan at the end of this reporting period. Meanwhile, the company's net assets fell from 5.852 billion yuan at the end of the previous year to 5.225 billion yuan at the end of the reporting period, and the balance ratio fell from 33.6% at the end of the previous year to 25.76% at the end of the reporting period. This shows that the size of the company's debt is decreasing, and the balance ratio is also declining.

In terms of profit, Kehua Biotech's operating income fell from 5.383 billion yuan in the same period last year to the end of the reporting period, operating profit fell from 2,276 million yuan in the same period last year to 79.1985 million yuan from the beginning of the year to the end of the reporting period, and net profit fell from 1,932 billion yuan in the same period last year to 485.696 million yuan from the beginning of the year to the end of the reporting period. This is mainly affected by factors such as changes in the market environment, increased competition in the industry, and implementation of collection policies.

In terms of cash flow, the net cash flow from Kehua Biotech's business activities fell from 1,474 billion yuan in the same period last year to -543 million yuan from the beginning of the year to the end of the reporting period, mainly due to a significant increase in payment of supplier payments and employee remuneration compared to the same period last year.

In summary, Kehua Biotech's financial situation in the third quarter of 2023 showed some pressure. Operating income and net profit both declined, and cash flow also declined. However, judging from the decline in the balance ratio, the scale of the company's debt is decreasing, which is beneficial to the company's long-term development.

For investors, although Kehua Biotech's short-term operating pressure is high, its position in the in vitro diagnostic market and the country's support policy for the medical industry make the company still have some potential for long-term development. Therefore, investors should fully consider the long-term development prospects of the company when making investment decisions.

This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment